Dechra Pharmaceuticals

Pharmaceuticals
DPH.L
GBX 2,826 1.1
Share price
$ 4 bn
Market Cap
$ 4.1 bn
Enterprise Value

Carbon footprint

3 Ton
GHG emissions per $ 1 mln investment
0.08x the weighted average for S&P 500
FY2021
How is this calculated?
+4.9%
YOY change in GHG emissions
In line with the +4.5% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

but has a science based goal that does not target absolute reductions but is still aligned with Paris Agreement according to SBTi

GHG emissions and Carbon intensity

Dechra Pharmaceuticals's GHG emissions (location-based) (Kt of CO2e)
Dechra Pharmaceuticals's Carbon intensity (Tons per 1 USDm)

Dechra Pharmaceuticals's carbon footprint

Dechra Pharmaceuticals reported Total CO2e Emissions - Location-Based Scope 1 + Scope 2 for the twelve months ending 30 June 2021 at 12 Kt (+0.57/+4.9% y-o-y). At the sime time, carbon intensity declined to 16 t (-1.8 /-10.1% y-o-y).

Dechra Pharmaceuticals's Scope 3 emissions was down at 1.9 Kt (-0.41 /-17.6% y-o-y). The decline accelerated compared to the CAGR of -7.2% since 2Q'19.

The company has not set a company-wide target for an absolute reduction in GHG emissions yet.

Dechra Pharmaceuticals also has a science-based goal that, however, does not appear to explicitly target a company-wide reduction in emissions in absolute terms. New World Development Company Limited commits to reduce absolute scope 1 and 2 GHG emissions 46.2% by FY2030 from a FY2019 base year. New World Development Company Limited also commits to reduce scope 3 GHG emissions from capital goods 22% per square meter of construction floor area by FY2030 from a FY2019 base year. New World Development Company Limited further commits to reduce scope 3 GHG emissions from downstream leased assets 29.8% per square meter of gross floor space within the same timeframe

Company environmental metrics

Show more...